BR0211192A - Conjugados de progenipoietina quimicamente modificados - Google Patents

Conjugados de progenipoietina quimicamente modificados

Info

Publication number
BR0211192A
BR0211192A BR0211192-6A BR0211192A BR0211192A BR 0211192 A BR0211192 A BR 0211192A BR 0211192 A BR0211192 A BR 0211192A BR 0211192 A BR0211192 A BR 0211192A
Authority
BR
Brazil
Prior art keywords
chemically modified
conjugates
progenipoietin
present
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
BR0211192-6A
Other languages
English (en)
Inventor
Ned R Siegel
Rory F Finn
Robert L Hills
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia Corp
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0211192A publication Critical patent/BR0211192A/pt
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"CONJUGADOS DE PROGENIPOIETINA QUIMICAMENTE MODIFICADOS". A presente invenção fornece umas Progenipoietinas (ProGPs) quimicamente modificadas preparadas aglutinando um polímero solúvel em água à proteína. A proteína quimicamente modificada de acordo com a presente invenção pode ter uma atividade de crescimento de neutrófilo de duração muito maior do que da ProGP não modificada, permitindo oportunidades de dose reduzida e planejamento.
BR0211192-6A 2001-06-22 2002-06-14 Conjugados de progenipoietina quimicamente modificados Withdrawn BR0211192A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30036201P 2001-06-22 2001-06-22
PCT/US2002/018810 WO2003000179A2 (en) 2001-06-22 2002-06-14 Chemically-modified progenipoietin conjugates

Publications (1)

Publication Number Publication Date
BR0211192A true BR0211192A (pt) 2004-10-26

Family

ID=23158770

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211192-6A Withdrawn BR0211192A (pt) 2001-06-22 2002-06-14 Conjugados de progenipoietina quimicamente modificados

Country Status (15)

Country Link
US (1) US20060052291A1 (pt)
EP (1) EP1404354A4 (pt)
JP (1) JP2005512951A (pt)
KR (1) KR20040069980A (pt)
CN (1) CN101426511A (pt)
BR (1) BR0211192A (pt)
CA (1) CA2450950A1 (pt)
CZ (1) CZ20033537A3 (pt)
EA (1) EA006368B1 (pt)
IL (1) IL159496A0 (pt)
MX (1) MXPA04000068A (pt)
NO (1) NO20035742L (pt)
PL (1) PL367410A1 (pt)
WO (1) WO2003000179A2 (pt)
ZA (1) ZA200309863B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006010176D1 (de) * 2005-02-16 2009-12-17 Micromet Ag Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
WO2010123827A1 (en) * 2009-04-20 2010-10-28 The Regents Of The University Of California Engineered demeter 5-methylcytosine dna glycosylase with improved yield, stability and solubility
KR200483859Y1 (ko) 2015-10-28 2017-07-04 주식회사 키유틸리티 충전장치 수납 및 휴대용 기기 거치용 장치
JP7046173B2 (ja) * 2017-10-11 2022-04-01 エランコ・ユーエス・インコーポレイテッド ブタｇ－ｃｓｆ変異体とその使用
JP7137625B2 (ja) * 2017-12-29 2022-09-14 エフ．ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024298A1 (fr) * 1993-04-21 1994-10-27 Institut Pasteur Implant biocompatible pour l'expression et secretion in vivo du compose therapeutique
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV
SE507527C2 (sv) * 1996-10-11 1998-06-15 Ericsson Telefon Ab L M Flerbandsmottagare som genererar en mellanfrekvens som är gemensam för de olika frekvensbanden, och förfarande för densamma
US6251665B1 (en) * 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom

Also Published As

Publication number Publication date
NO20035742D0 (no) 2003-12-19
WO2003000179A3 (en) 2003-12-11
PL367410A1 (en) 2005-02-21
EP1404354A2 (en) 2004-04-07
NO20035742L (no) 2004-02-23
ZA200309863B (pt) 2006-06-28
KR20040069980A (ko) 2004-08-06
WO2003000179A2 (en) 2003-01-03
CZ20033537A3 (cs) 2004-08-18
MXPA04000068A (es) 2005-06-06
US20060052291A1 (en) 2006-03-09
CA2450950A1 (en) 2003-01-03
EA200400070A1 (ru) 2004-06-24
CN101426511A (zh) 2009-05-06
EA006368B1 (ru) 2005-12-29
IL159496A0 (en) 2004-06-01
EP1404354A4 (en) 2005-04-20
JP2005512951A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
BR0316716A (pt) Conjugados quimicamente modificados do hormÈnio do crescimento humano
BR0214451A (pt) conjugados do hormÈnio do crescimento humano quimicamente modificado
WO2005035003A3 (en) Compositions and methods for increasing drug efficiency
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
WO2002100437A3 (en) Ophthalmic compositions comprising hyaluronic acid
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
BR0213207A (pt) remodelagem e glicoconjugação de peptìdeos
BR0108713A (pt) Expressão hìbrida de proteìnas de neisseria
DE69609982T2 (de) Lipopolyamine als transfectionsmittel und ihre pharmazeutischen anwendungen
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
BR0210568A (pt) Conjugado, uso de um conjugado, composição farmacêutica, e, método para tratar câncer em um mamìfero
ATE485049T1 (de) Physiologisch aktive zusammensetzung gegen diabetes
MX2009006410A (es) Conjugados de polimero-oligonucleotido, proteina y/o peptido.
DE50205968D1 (de) Heparin-haltiges ophthalmikum
BR0210348A (pt) Material polimérico, contendo um ácido latente
BR0211192A (pt) Conjugados de progenipoietina quimicamente modificados
NO20034504L (no) Erytropoietin forbedrer in vivo kjemoterapiindusert toksisitet
BR0315178A (pt) Eritropoietina: remodelagem e glicoconjugação de eritropoietina
WO2002062304A3 (de) Kosmetische und/oder pharmazeutische mittel acylierte aminosäure und proteinkondensat enthaltend.
WO2004039326A3 (en) Propofol with cysteine
WO2002020619A3 (en) HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
DE602006008678D1 (de) Zahnimplantat
BR0212287A (pt) Proteìna de ligação caspase-8, sua preparação e uso
WO2001076639A3 (en) Chemically-modified myelopoietin conjugates
ATE474582T1 (de) Pharmazeutische zusammensetzung enthaltend glucan aus mikroalgen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.